Patents Assigned to Fountain Biopharma Inc.
  • Method of treating autoimmune disease by administering antibodies to interleukin-6
    Patent number: 10370443
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 6, 2019
    Assignee: Fountain Biopharma Inc.
    Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
  • USES OF ANTIBODIES TO INTERLEUKIN-6 IN CANCER TREATMENT
    Publication number: 20170362317
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 21, 2017
    Applicant: Fountain Biopharma Inc.
    Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
  • Uses of antibodies to interleukin-6 in cancer treatment
    Patent number: 9758580
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: September 12, 2017
    Assignee: Fountain Biopharma Inc.
    Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
  • METHODS FOR PRODUCING RECOMBINANT GLYCOPROTEINS WITH MODIFIED GLYCOSYLATION
    Publication number: 20170145463
    Abstract: Genetically engineered host animal cells capable of producing glycoproteins having modified glycosylation patterns, e.g., defucosylation and/or monoglycosylation. Such host animal cells can be engineered to express fucosidase, endoglycosidase or both.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 25, 2017
    Applicant: Fountain Biopharma Inc.
    Inventors: NIEN-YI CHEN, Che-Haorz Wu, Hung-Chi Chen, Winston Town
  • Methods for producing recombinant glycoproteins with modified glycosylation
    Patent number: 9540673
    Abstract: Genetically engineered host animal cells capable of producing glycoproteins having modified glycosylation patterns, e.g., defucosylation and/or monoglycosylation. Such host animal cells can be engineered to express fucosidase, endoglycosidase or both.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 10, 2017
    Assignee: Fountain Biopharma Inc.
    Inventors: Nien-Yi Chen, Che-Haorz Wu, Hung-Chi Chen, Winston Town
  • ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF
    Publication number: 20160185851
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Application
    Filed: December 31, 2015
    Publication date: June 30, 2016
    Applicant: Fountain Biopharma Inc.
    Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
  • Antibodies to interleukin-6
    Patent number: 9234035
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 12, 2016
    Assignee: Fountain Biopharma Inc.
    Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
  • METHODS FOR PRODUCING RECOMBINANT GLYCOPROTEINS WITH MODIFIED GLYCOSYLATION
    Publication number: 20150259720
    Abstract: Genetically engineered host animal cells capable of producing glycoproteins having modified glycosylation patterns, e.g., defucosylation and/or monoglycosylation. Such host animal cells can be engineered to express fucosidase, endoglycosidase or both.
    Type: Application
    Filed: March 17, 2015
    Publication date: September 17, 2015
    Applicant: Fountain Biopharma Inc.
    Inventors: Nien-Yi Chen, Che-Haorz Wu, Hung-Chi Chen, Winston Town
  • ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF
    Publication number: 20140112935
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Application
    Filed: October 18, 2013
    Publication date: April 24, 2014
    Applicant: Fountain Biopharma Inc.
    Inventors: Willie Lin, Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao